- Home
- NVRI vs ORKA Comparison
NVRI vs ORKA Comparison
Compare NVRI & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVRI
- ORKA
- Stock Information
- Founded
- NVRI 1853
- ORKA 2004
- Country
- NVRI United States
- ORKA United States
- Employees
- NVRI N/A
- ORKA N/A
- Industry
- NVRI Diversified Commercial Services
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- NVRI Miscellaneous
- ORKA Health Care
- Exchange
- NVRI Nasdaq
- ORKA Nasdaq
- Market Cap
- NVRI 996.0M
- ORKA 1.2B
- IPO Year
- NVRI N/A
- ORKA N/A
- Fundamental
- Price
- NVRI $18.17
- ORKA $30.36
- Analyst Decision
- NVRI
- ORKA Strong Buy
- Analyst Count
- NVRI 0
- ORKA 9
- Target Price
- NVRI N/A
- ORKA $45.22
- AVG Volume (30 Days)
- NVRI 2.0M
- ORKA 413.4K
- Earning Date
- NVRI 11-10-2025
- ORKA 11-12-2025
- Dividend Yield
- NVRI N/A
- ORKA N/A
- EPS Growth
- NVRI N/A
- ORKA N/A
- EPS
- NVRI N/A
- ORKA N/A
- Revenue
- NVRI $2,244,061,000.00
- ORKA N/A
- Revenue This Year
- NVRI N/A
- ORKA N/A
- Revenue Next Year
- NVRI $3.72
- ORKA N/A
- P/E Ratio
- NVRI N/A
- ORKA N/A
- Revenue Growth
- NVRI N/A
- ORKA N/A
- 52 Week Low
- NVRI $4.72
- ORKA $5.49
- 52 Week High
- NVRI $18.59
- ORKA $29.98
- Technical
- Relative Strength Index (RSI)
- NVRI 85.04
- ORKA 62.69
- Support Level
- NVRI $12.87
- ORKA $26.52
- Resistance Level
- NVRI $18.59
- ORKA $29.87
- Average True Range (ATR)
- NVRI 0.76
- ORKA 2.30
- MACD
- NVRI 0.47
- ORKA -0.12
- Stochastic Oscillator
- NVRI 93.55
- ORKA 77.67
About NVRI Enviri Corporation
Enviri Corp is a market-leading, provider of environmental solutions for industrial and specialty waste streams, and equipment and technology for the rail sector. The company's current operations consist of three divisions: Harsco Environmental, Harsco Rail, and Clean Earth. The company gains its revenue from Harsco Environmental segment. Geographically company operates in USA and International Countries, with majority revenue from USA.
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.